Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S 49076 plus bevacizumab in recurrent glioblastoma multiforme
ISRCTN11619481Phase 2Completed
- Sponsor
- Servier
- Start
- Oct 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of s49076 and bevacizumab in glioblastoma (GBM), sponsored by Servier. Primary endpoints: Dose-limiting toxicity and recommended phase II dose, Safety profile and 1 more. Started Oct 2014; status: completed.
02
Drugs
s49076bevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ISRCTN11619481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11619481.